^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data

Published date:
12/14/2021
Excerpt:
Final data demonstrated improved responses per independent review facility with brentuximab vedotin vs We report final data from ALCANZA (median follow-up, 45.9 months). Adults with previously treated CD30-expressing MF/C-ALCL were randomly assigned to brentuximab vedotin...physician's choice: ORR4; 54.7% vs 12.5% (P < .001); complete response, 17.2% vs 1.6% (P = .002). Median PFS with brentuximab vedotin vs physician's choice was 16.7 months vs 3.5 months (P < .001). Median time to the next treatment was significantly longer with brentuximab vedotin than with physician's choice (14.2 vs 5.6 months; hazard ratio, 0.27; 95% confidence interval, 0.17-0.42; P < .001)...These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician's choice in CD30-expressing MF or C-ALCL.
DOI:
10.1182/bloodadvances.2021004710
Trial ID:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Peripheral T-cell Lymphoma)
New
Excerpt:
ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of adult patients with:...Previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Excerpt:
......
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Excerpt:
...Rate of objective global response defined as proportion of patients achieving complete response (CR)/partial response (PR) that lasts at least 4 months`Complete response defined as proportion of patients achieving CR according to Olsen criteria`Progression free survival (PFS) according to Olsen criteria`Change in pruritus visual analogue scale (VAS)`CD30 expression assessed by lymph node and/or skin biopsies via immunochemistry...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Excerpt:
...Patients with relapsed/refractory mycosis fungoides, who have ever expressed or currently express at least 1% CD30 assessed by biopsy within 6 months prior to study enrollment, are eligible....
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Excerpt:
...Response rate is percentage of participants with skin lesions that express CD30+ receiving SGN-35 in primary cutaneous ALCL, MF, and extensive lymphomatoid papulosis whose best response during the observation period is a Partial Response (PR), regression of measurable disease, or Complete Response (CR), complete disappearance of all clinical evidence of disease, (i.e. at least moderate improvement). ...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

Excerpt:
...Patients with either Hodgkin lymphoma or T-cell lymphoma must have expression of CD30 in ≥10% of lymphoma cells....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Imaging study with brentuximab in patients with lymphoma Beeldvormend onderzoek met brentuximab bij patiënten met lymfeklierkanker

Excerpt:
...• A feasible and optimized 89Zr-brentuximab imaging protocol in patients with CD30+ lymphomas• Safety profile, pharmacokinetics (PK), and pharmacodynamics (PD) of the tracer 89Zr-brentuximab• The relationship between 89Zr-brentuximab biodistribution (tumor uptake) and CD30 protein expression (IHC), soluble CD30 measurements (ELISA), as well as CD30 RNA expression (nanostring). ...
Less C2 evidence
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine

Published date:
05/13/2021
Excerpt:
We report the successful treatment of a 68-year-old man who suffered PCGD-TCL with a combination of Brentuximab Vedotin and Gemcitabine after the failure of two lines of previous chemotherapy. CD30 expression was only partial.
Secondary therapy:
gemcitabine
DOI:
10.1186/s40164-021-00225-2